Ahmedabad: Zydus Lifesciences Ltd, a global healthcare company announced that it has entered into an agreement with CVS Caremark, a CVS Health company to add Zituvio, Zituvimet and Zituvimet ...

Zydus Pharmaceuticals USA Inc President & CEO Punit Patel said the relationship is a strong validation of Zydus' strategic investments in the new drug applications portfolio.

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

Zydus Lifesciences (including its subsidiaries/affiliates, hereafter referred to as 'Zydus'), a global innovation driven healthcare company announced that it has entered into an agreement with CVS ...

Shares of CVS Health Corp. CVS inched 0.11% higher to $45.82 Monday, on what proved to be an all-around mixed trading session ...

Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $68.07, accompanied by ...

All of the commercial prescriptions dispensed at CVS pharmacies will be processed through its CostVantage reimbursement model ...

CVS Health CVS shareholders are experiencing a rough period as the stock continues to face significant downward pressure. Recent reports about the company's strategic restructuring plans have placed ...

Aetna, the health, medical and benefits insurance unit of CVS Health, is back in the insurance-linked securities (ILS) market and seeking what could become its largest issuance in the long-standing ...

CVS Health has been named as a Top 25 dividend stock, according the most recent Dividend Channel "DividendRank" report.

CVS Health has announced that starting this year, all commercial prescriptions dispensed through CVS Pharmacy will be contracted through its new CVS CostVantage reimbursement model.